Phase Forward Signs Multi-Year, Multi-Million Dollar Contract Commitment with Everest Clinical Research Services
Company News Release
WALTHAM, Mass.-Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, today announced a multi-year, multi-million dollar agreement with Everest Clinical Research Services Inc. (Everest), a contract research organization (CRO). This agreement extends a contract signed in 2007 and calls for Everest to leverage both Phase Forward’s InForm Integrated Trial Management (ITM) and its hosted Central Designer module Electronic Data Capture (EDC) solution.
Everest Clinical Research Services Inc.-created by a group of former colleagues of Pharmacia Corporation-has been an independent CRO since Pharmacia’s acquisition by Pfizer five years ago. Everest enjoys partnerships or preferred vendor relationships with a number of major pharmaceutical companies as well as other smaller pharmaceutical and biotechnology companies. The company has offices in Toronto, Ontario, and Little Falls, New Jersey.
“EDC technology is a key enabler of our core clinical data management service,” said Irene Zhang, president and CEO, Everest Clinical Research Services Inc. “Phase Forward’s Central Designer study design environment and InForm EDC products have proven an effective solution for providing our clients with the core components of this service: high quality and timely data collection, cleaning and database lock. By adopting this technology in-house, we expect to bring even greater efficiencies to the management of clinical trial data for our trial sponsors.”
“Today’s announcement emphasizes the range of CROs with which Phase Forward successfully collaborates,” said Mike Davies, vice president, global CRO partnerships at Phase Forward. “We work with CROs of all sizes and profiles, mindful of the unique needs of small- to medium-sized CROs like Everest, and are committed to working together to bring the benefits of EDC to their customers. We are focused on both the operational and commercial success of Everest.”
Phase Forward’s CRO partnership strategy is designed to assist CRO clients in achieving success in both the short and long term. Its customized structure and flexible pricing options help CROs of all sizes to invest in their own capabilities and capitalize on new growth opportunities. Across all of its solutions, Phase Forward has over 90 CRO customers as of the end of 2008.
About Everest Clinical Research Services Inc. Everest Clinical Research Services Inc. offers the following services:
Clinical Data Management
Biostatistics and Statistical Programming
Trial Subject Randomization using IWRS (Interactive Web Response System)
Trial Drug Dispensing and Inventory Management using IWRS
Development and Maintenance of Web Portals and Study Websites
Medical Writing for Clinical Study Reports, Abstracts, Manuscripts, Posters, etc.
Regulatory Submission Support Using eCTD
Administration of Clinical Trial Data and Safety Monitoring Boards
Trial Management and Site Monitoring Using Partnering Clinical Management Firms Everest has experience in Phase I through Phase IV clinical trials in many therapeutic areas. Additional information about Everest Clinical Research Services Inc. is available at www.ecrscorp.comAbout Phase Forward Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. The company offers proven solutions for electronic data capture (InForm™), phase I clinic automation (LabPas™), clinical data management (Clintrial™), clinical trials signal detection (CTSD™), strategic pharmacovigilance (Empirica Signal™) and Signal Management, adverse event reporting (Empirica Trace™), applied data standards (WebSDM™), Web-integrated interactive response technologies (Clarix™), and clinical data analysis and reporting automation and compliance (Waban SCE/CDR, Waban SMS and Waban LIMS). In addition, the company provides services in the areas of application implementation, hosting and validation, data integration, business process optimization, safety data management and industry standards. Phase Forward’s products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 280 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at www.phaseforward.com Cautionary Statement Certain statements made in this press release that are not based on historical information are forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release contains express or implied forward-looking statements relating to, among other things, the performance and features of Phase Forward’s products and services, demand for Phase Forward’s products and services, future business and operations plans of a Phase Forward customer, and the ability of Phase Forward’s customers to realize benefits from the use of Phase Forward’s products and services. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond Phase Forward's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things, the ability of Phase Forward’s customers to realize benefits from the use of its products and services, the possibility that customers’ needs or plans may change over time, the possibility that the level of demand for Phase Forward’s products and services may vary, regulatory changes and competition. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Phase Forward undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by Phase Forward, see the disclosure contained in Phase Forward's public filings with the Securities and Exchange Commission including, without limitation, its most recent Annual Report on Form 10-K.